Using advanced nanomedicine for innovative therapies

At a Glance

  • Founded: 1997, head office in Berlin, Germany
  • Management Board: Dr. Ben J. Lipps (CEO), Prof. Hoda Tawfik (Chief Medical Officer), Christian von Volkmann (CFO)
  • Employees: 25 employees plus a production company with 14 employees
  • Listed on the Frankfurt Stock Exchange (MF6)
  • Strong IP protection: 17 international patent families, approx. 100 single patents, and 65 patent applications
  • NanoTherm® therapy launched in 2011

Recent Highlights

  • First and only nanotechnology-based therapy (NanoTherm®) with European regulatory approval (CE conformity marking) for the treatment of brain tumors
  • NanoActivator® devices installed in Berlin, Münster, Kiel, Cologne and Frankfurt; study centers without own device established in Düsseldorf and Giessen
  • End of March 2014 enrollment of the first patient into the new glioblastoma study MF1001
  • First US commercial glioblastoma patient treated in Germany in Q1 2015
  • Incorporation of the US affiliate MagForce USA, Inc. in March 2014 to introduce NanoTherm® therapy for the treatment of glioblastoma and prostate cancer in the US
  • Pre-submission meeting at the FDA to conduct a study with NanoTherm® therapy in the US in May 2014
  • Pre-IDE Meeting on MagForce's NanoTherm® Prostate Cancer Therapy Pre-Submission in January 2015 and filing IDE in May 2015
  • First USA NanoActivator® installed in Seattle, Washington, in November 2015. It will be utilized in the Focal Thermal Ablation Registration Study for Prostate Cancer
  • Initiation of Commercial NanoTherm® Treatments for Brain Cancer at Vivantes Friedrichshain in collaboration with Charité - Universitätsmedizin Berlin in April 2016
  • Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of Mithril Capital Management in August 2014
  • Successful completion of a capital increase of MagForce AG in November 2014 with gross proceeds of €10.2million

Compliant with European Standard